AbbVie Inc. (ABBV)
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
When it comes to targeting discounted ideas in the equities sector, undervalued blue-chip stocks offer some of the most compelling prospects. First and foremost, blue chips earn the status through decades of business and earnings expansion.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie (ABBV) Laps the Stock Market: Here's Why
AbbVie (ABBV) closed the most recent trading day at $170.46, moving +0.61% from the previous trading session.
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Top 2 dividend stocks to buy for long-term gains
Dividend stocks benefit from falling interest rates as money managers shift to income-oriented equities with yields above the S&P 500.
Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars
AbbVie's top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
AbbVie said on Thursday its therapy to treat patients with a type of ovarian cancer has met the main goal of a mid-stage trial.
Hedge Fund Favorites: 7 Stocks to Buy When You're Feeling Jittery
With the market entering a historically challenging season (due to the adage buy in May and go away), jittery investors may want to turn to stocks to buy tacitly endorsed by the hedge funds and other institutional players. Basically, if the big dogs like these ideas, you might want to consider adding some yourself.
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that provide life-changing drugs.
2 High-Yield Dividend Stocks to Buy Right Now
High-yield dividend stocks typically outperform the broader markets over long periods. AbbVie and Pfizer are two attractively priced high-yield dividend stocks worth considering right now.
The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme
The timing is perfect for loading up on dividend stocks as market experts expect the S&P 500 to increase 4% in June following a 5% rise in May as three potential rate cuts loom, possibly boosting already solid corporate profitability. Meanwhile, 97% of S&P 500 companies reported first-quarter results that were 3% better than consensus.
